Lantheus Holdings Inc (LNTH) said Tuesday that it entered a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction.
The transaction will consist of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments, the company said.
The acquisition has been approved by the boards of directors of both companies and is expected to close in the second half of 2025.
Lantheus reaffirmed its 2024 financial guidance. The company previously said it expects 2024 adjusted EPS of between $6.65 and $6.70 on revenue of between $1.51 billion and $1.52 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.